PDS Biotechnology Corp Surprises with Earnings Beat Amid Revenue Concerns and Stock Volatility
PDS Biotechnology Corp’s Q1 2025 earnings beat expectations, but lack of revenue raises concerns about its path to profitability and long-term viability in the competitive biotech industry.
3 minutes to read